Fady Ibraham Malik Cytokinetics Inc (CYTK) insider trading activity

Fady Ibraham Malik is EVP Research & Development of CYTOKINETICS INC. Currently has a direct ownership of 140,255 shares of CYTK, which is worth approximately $6.06 Million. The most recent transaction as insider was on Apr 08, 2025, when has been sold 2,000 shares (Common Stock) at a price of $36.18 per share, resulting in proceeds of $72,360. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 140K

20.84% 3M change

1.33% 12M change

Total Value Held $6.06 Million

Fady Ibraham Malik Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Apr 08 2025	SELL Open market or private sale	$72,360 $36.18 p/Share	2,000 Reduced 1.41%	140,255 Common Stock
Apr 08 2025	BUY Exercise of conversion of derivative security	$21,200 $10.6 p/Share	2,000 Added 1.39%	142,255 Common Stock
Mar 19 2025	SELL Bona fide gift	-	200 Reduced 0.14%	140,255 Common Stock
Mar 18 2025	SELL Open market or private sale	$87,160 $43.58 p/Share	2,000 Reduced 1.4%	140,455 Common Stock
Mar 18 2025	BUY Exercise of conversion of derivative security	$21,200 $10.6 p/Share	2,000 Added 1.38%	142,455 Common Stock
Mar 17 2025	SELL Open market or private sale	$194,783 $44.38 p/Share	4,389 Reduced 4.16%	101,005 Common Stock
Mar 14 2025	BUY Grant, award, or other acquisition	-	39,450 Added 21.41%	144,844 Common Stock
Mar 06 2025	SELL Open market or private sale	$356,025 $43.27 p/Share	8,228 Reduced 7.24%	105,394 Common Stock
Mar 04 2025	SELL Open market or private sale	$85,000 $42.5 p/Share	2,000 Reduced 1.69%	116,071 Common Stock
Mar 04 2025	BUY Exercise of conversion of derivative security	$21,200 $10.6 p/Share	2,000 Added 1.67%	118,071 Common Stock
Mar 03 2025	SELL Open market or private sale	$105,013 $42.88 p/Share	2,449 Reduced 2.11%	113,622 Common Stock
Feb 18 2025	SELL Open market or private sale	$91,960 $45.98 p/Share	2,000 Reduced 1.69%	116,071 Common Stock
Feb 18 2025	BUY Exercise of conversion of derivative security	$21,200 $10.6 p/Share	2,000 Added 1.67%	118,071 Common Stock
Feb 04 2025	SELL Open market or private sale	$96,120 $48.06 p/Share	2,000 Reduced 1.69%	116,071 Common Stock
Feb 04 2025	BUY Exercise of conversion of derivative security	$21,200 $10.6 p/Share	2,000 Added 1.67%	118,071 Common Stock
Jan 21 2025	SELL Open market or private sale	$91,840 $45.92 p/Share	2,000 Reduced 1.69%	116,071 Common Stock
Jan 21 2025	BUY Exercise of conversion of derivative security	$21,200 $10.6 p/Share	2,000 Added 1.67%	118,071 Common Stock
Jan 07 2025	SELL Open market or private sale	$98,640 $49.32 p/Share	2,000 Reduced 1.69%	116,071 Common Stock
Jan 07 2025	BUY Exercise of conversion of derivative security	$21,200 $10.6 p/Share	2,000 Added 1.67%	118,071 Common Stock
Dec 10 2024	SELL Open market or private sale	$369,672 $50.64 p/Share	7,300 Reduced 5.92%	116,071 Common Stock
Dec 10 2024	BUY Exercise of conversion of derivative security	$42,188 $7.96 p/Share	5,300 Added 4.12%	123,371 Common Stock
Dec 03 2024	SELL Payment of exercise price or tax liability	$104,462 $51.51 p/Share	2,028 Reduced 1.75%	114,071 Common Stock
Dec 03 2024	BUY Grant, award, or other acquisition	-	8,000 Added 6.35%	118,071 Common Stock
Nov 26 2024	SELL Open market or private sale	$366,095 $50.15 p/Share	7,300 Reduced 6.13%	111,878 Common Stock
Nov 26 2024	BUY Exercise of conversion of derivative security	$42,188 $7.96 p/Share	5,300 Added 4.26%	119,178 Common Stock

Also insider at

RCKT

ROCKET PHARMACEUTICALS, INC. Healthcare

FIM